Twist Bioscience Corporation $TWST Stock Position Lowered by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP reduced its holdings in Twist Bioscience Corporation by 3.2%, bringing its total ownership to approximately 1.27%, valued at about $29.9 million.
• Insider selling was reported, with CEO Emily M. Leproust and CFO Adam Laponis selling shares, leading to a decrease in their ownership by 0.26% and 2.31%, respectively.
• Analyst opinions vary, with nine analysts giving a "Buy" rating, while the average target price for the stock is currently $49.40.

Wellington Management Group LLP lessened its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 3.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 760,951 shares of the company's stock after selling 25,361 shares during the quarter. Wellington Management Group LLP owned approximately 1.27% of Twist Bioscience worth $29,875,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. American Century Companies Inc. grew its holdings in shares of Twist Bioscience by 0.9% during the first quarter. American Century Companies Inc. now owns 763,406 shares of the company's stock worth $29,971,000 after buying an additional 7,054 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in Twist Bioscience in the 1st quarter worth approximately $3,977,000. E Fund Management Co. Ltd. raised its holdings in Twist Bioscience by 39.9% in the 1st quarter. E Fund Management Co. Ltd. now owns 9,279 shares of the company's stock valued at $364,000 after acquiring an additional 2,646 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Twist Bioscience by 1,121.3% in the first quarter. Russell Investments Group Ltd. now owns 108,834 shares of the company's stock valued at $4,273,000 after purchasing an additional 99,923 shares during the period. Finally, Nuveen LLC acquired a new position in Twist Bioscience in the first quarter valued at $31,960,000.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction on Friday, June 20th. The stock was sold at an average price of $35.76, for a total transaction of $60,005.28. Following the sale, the chief executive officer owned 645,782 shares of the company's stock, valued at $23,093,164.32. The trade was a 0.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the sale, the chief financial officer directly owned 103,569 shares in the company, valued at $3,951,157.35. This represents a 2.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,250 shares of company stock worth $193,852 in the last ninety days. 3.01% of the stock is owned by company insiders.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST traded down $0.60 during mid-day trading on Thursday, hitting $26.59. The company had a trading volume of 1,539,904 shares, compared to its average volume of 1,190,056. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -18.34 and a beta of 2.36. Twist Bioscience Corporation has a 12 month low of $24.28 and a 12 month high of $55.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The firm's 50 day simple moving average is $33.09 and its two-hundred day simple moving average is $35.88.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Robert W. Baird dropped their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Finally, The Goldman Sachs Group cut their target price on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $49.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.